Kondo Yoshitaka, Nagasaka Takeshi, Kobayashi Satoru, Kobayashi Naoya, Fujiwara Toshiyoshi
Hepatogastroenterology. 2014 Mar-Apr;61(130):349-53.
BACKGROUND/AIMS: PuraMatrix is a synthetic material consisting of 16-amino acid peptides that self-assemble into nanofibers, previously used as a scaffold for functional cell cultures. We conducted a clinical study to determine the safety and sealing properties of PuraMatrix in post-operative lymphorrhea following pelvic surgery in humans.
A total of 20 patients who underwent rectal cancer resection were analyzed. The study group (n = 10) consisted of patients who received PuraMatrix, matched with a control group (n = 10) of patients operated on conventionally.
During the 2 to 3 month follow-up period, there were no abnormal findings or adverse events in any the patients who received PuraMatrix. We found that the patients who received PuraMatrix had significantly reduced post-operative drainage volumes compared with the patients in the control group.
PuraMatrix is a safe and effective bio-compatible sealing material for the management of post-operative peritoneal effusion following pelvic surgery.
背景/目的：PuraMatrix是一种由16种氨基酸肽组成的合成材料，可自组装成纳米纤维，以前用作功能性细胞培养的支架。我们进行了一项临床研究，以确定PuraMatrix在人类盆腔手术后淋巴漏中的安全性和封闭特性。
共分析了20例接受直肠癌切除术的患者。研究组（n = 10）由接受PuraMatrix的患者组成，并与常规手术的对照组（n = 10）患者相匹配。
在2至3个月的随访期内，接受PuraMatrix的患者均未发现异常或不良事件。我们发现，与对照组患者相比，接受PuraMatrix的患者术后引流量明显减少。
PuraMatrix是一种安全有效的生物相容性封闭材料，用于治疗盆腔手术后的腹膜积液。
